Importantly, recombinant IL-7 has undergone clinical testing alone or alongside other immunotherapies to stimulate the antitumor activity of T cells in refractory cancers (NCT05075603, NCT04588038, NCT04710043) [11]. This evidence concerns the gene IL7 and cancer.